Anupam Rasayan revenue jumps 65% in FY26 as margins slip
Revenue growth outpaced profitability for the year, while quarterly net profit dropped 11% year-on-year.
— 2 earlier stories on Anupam Rasayan India Ltd. →What's new
- FY26 revenue grew 65% year-on-year.
- EBITDA margins for the year contracted to 23% from 28%.
- Q4 profit after tax fell 11% compared to the same quarter last year.
Why this matters
The company is scaling its top line, but the margin compression shows that growth is becoming more expensive. Investors must weigh the impact of recent acquisitions like Jayhawk against the reality of declining quarterly profitability.
What we're watching
- Whether margins recover in FY27.
- The integration progress of the Jayhawk and Bliss GVS Pharma deals.
- Management commentary on the drivers behind the Q4 profit decline.
The full read
Anupam Rasayan reported 65% year-on-year revenue growth for FY26, but the expansion came at a steep cost to profitability. EBITDA margins for the year slipped to 23% from 28%.
Margins are shrinking.
The trend continued into the final quarter, where profit after tax dropped 11% year-on-year, proving that the company's aggressive pursuit of scale through the Jayhawk acquisition and the Bliss GVS Pharma deal is currently failing to deliver the expected bottom-line efficiency. Investors should remain cautious until management demonstrates that these new assets can actually improve, rather than dilute, the firm's core operating margins.
Questions answered
- How did Anupam Rasayan perform in FY26?
- The company achieved 65% year-on-year revenue growth. EBITDA margins tightened to 23% from 28% in the previous year.
- What was the trend for profitability in the final quarter?
- Profit after tax for Q4 declined 11% year-on-year.
- Are there specific acquisitions impacting these results?
- The results include the impact of the Jayhawk acquisition and the deal with Bliss GVS Pharma.
- What is the primary trend in these financial results?
- Revenue is growing rapidly, but profitability is declining as margins contract.
Story so far
All notes on ANURAS →- Today · 8:27 PM IST Anupam Rasayan revenue jumps 65% in FY26 as margins slip
- today Anupam Rasayan buys control of Bliss GVS Pharma for ₹2,200 crore
- today Anupam Rasayan buys 74% of Bliss GVS Pharma to enter drug sector